

AMENDMENTS

IN THE CLAIMS

28. (Twice Amended) A method of treating diseases directly affecting liver function comprising:  
inducing a semi-synchronous wave of liver cell proliferation by concurrently contacting the  
liver cells with tri-iodothyronine (T3) and keratinocyte growth factor (KGF);  
contacting the liver cells with a retroviral vector containing a nucleic acid that encodes a  
RNA, protein or polypeptide to be expressed;  
and expressing the RNA, protein or polypeptide.
35. (Twice Amended) A method of treating diseases directly affecting liver function comprising:  
the administration of a composition comprising an effective amount of tri-iodothyronine (T3)  
and an effective amount of keratinocyte growth factor (KGF), wherein the composition is in an  
effective amount that induces a semi-synchronous wave of liver cell proliferation upon  
administration *in vivo* in a subject;  
further comprising administering to the liver, subsequent to the liver cell proliferation, a  
retroviral vector containing a nucleic acid that encodes a RNA, protein or polypeptide to be  
expressed, wherein expression of the RNA, protein or polypeptide will treat a condition; and  
expressing the RNA, protein or polypeptide, thereby treating the condition.
51. (Twice Amended) A method for treating or preventing cirrhosis of the liver  
comprising concurrently administering to a subject an effective amount of T3 and an effective